<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04634188</url>
  </required_header>
  <id_info>
    <org_study_id>Universitas Sumatera Utara</org_study_id>
    <nct_id>NCT04634188</nct_id>
  </id_info>
  <brief_title>Role and Value of Inflammatory Markers in Brain Tumors : A Case Controlled Study</brief_title>
  <official_title>Role and Value of Inflammatory Markers in Brain Tumors : A Case Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitas Sumatera Utara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitas Sumatera Utara</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a case controlled analytical study that analyzes the relationship between&#xD;
      levels of inflammatory markers with the type of brain tumor. Samples of 35 people were then&#xD;
      categorized according to the variables above and analyzing to measure its significance&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a case controlled analytical study to find the relationship between levels of&#xD;
      inflammatory markers in patients with brain tumors. Samples were collected from patients at&#xD;
      Haji Adam Malik Hospital in Medan, then the patient's blood serum was taken to be checked for&#xD;
      these variables. Sample collection began in March - September 2020. The sample obtained was&#xD;
      35 people who met the inclusion and exclusion criteria.&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
        1. Willing to be a sample&#xD;
&#xD;
        2. Complete medical records&#xD;
&#xD;
        3. Head scan and head contrast MRI have been performed to confirm the patient's diagnosis&#xD;
           with a brain tumor&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        1. The patient's age is over 70 years&#xD;
&#xD;
        2. Patients with high comorbidities such as kidney failure, heart disease, diabetes, and&#xD;
           others&#xD;
&#xD;
        3. Patients with a history of brain tumor surgery or previous brain tumor treatment&#xD;
&#xD;
      Samples were categorized based on demographic data (age and gender), then the samples were&#xD;
      categorized based on the type of brain tumor suffered. Once categorized, the levels of&#xD;
      inflammatory markers was examined. Specimens were taken from the patient's peripheral blood&#xD;
      examination and analyzed in laboratorium. The results of these examinations are grouped on a&#xD;
      nominal scale, and analyzed statistically.&#xD;
&#xD;
      Based on this analysis, it will be determined whether there is a significant relationship&#xD;
      between levels of inflammatory markers in the incidence of brain tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Actual">October 1, 2020</completion_date>
  <primary_completion_date type="Actual">September 1, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Value of Procalcitonin</measure>
    <time_frame>February-April 2020</time_frame>
    <description>Value of Procalcitonin in each group (Meningioma Group, Glioma Group and Brain metastasis group)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Value of C-Reactive Protein</measure>
    <time_frame>April- June 2020</time_frame>
    <description>Value of C-Reactive Protein in each group (Meningioma Group, Glioma Group and Brain metastasis group)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Value of Neutrophyl to Lymphocyte Ratio (NLR)</measure>
    <time_frame>June- August 2020</time_frame>
    <description>Value of NLR in each group (Meningioma Group, Glioma Group and Brain metastasis group)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Demographic of samples</measure>
    <time_frame>August- October 2020</time_frame>
    <description>Demographic of each samples such as age, gender, Glassgow coma scale and Karnofsky score</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">35</enrollment>
  <condition>Brain Tumor</condition>
  <arm_group>
    <arm_group_label>Meningioma Group</arm_group_label>
    <description>This group is based on the type of histopathology and MRI images that lead to a meningioma type brain tumor.&#xD;
After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glioma Group</arm_group_label>
    <description>This group is based on the type of histopathology and MRI images that lead to a glioma type brain tumor.&#xD;
After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brain Metastasis Group</arm_group_label>
    <description>This group is based on the type of histopathology and MRI images that lead to a metastasis brain tumor type After grouping, blood serum samples was collected to check the value of CRP, procalcitonin and NLR. The data were entered in a table and then compared with values from other types of brain tumors.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Procalcitonin</intervention_name>
    <description>Samples were categorized based on demographic data (age and gender), then the samples were categorized based on the type of brain tumor suffered. Once categorized, the levels of inflammatory markers was examined. Specimens were taken from the patient's peripheral blood examination and analyzed in laboratorium. The results of these examinations are grouped on a nominal scale, and analyzed statistically</description>
    <arm_group_label>Brain Metastasis Group</arm_group_label>
    <arm_group_label>Glioma Group</arm_group_label>
    <arm_group_label>Meningioma Group</arm_group_label>
    <other_name>C-Reactive Protein (CRP)</other_name>
    <other_name>Neutrophyl to Lymphocyte Ratio (NLR)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Samples were collected from patients at Haji Adam Malik Hospital in Medan, Sample&#xD;
        collection began in March - September 2020&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing to be a sample&#xD;
&#xD;
          2. Complete medical records&#xD;
&#xD;
          3. Head scan and head contrast MRI have been performed to confirm the patient's diagnosis&#xD;
             with a brain tumor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The patient's age is over 70 years&#xD;
&#xD;
          2. Patients with high comorbidities such as kidney failure, heart disease, diabetes, and&#xD;
             others&#xD;
&#xD;
          3. Patients with a history of brain tumor surgery or previous brain tumor treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Faculty of Medicine Universitas Sumatera Utara</name>
      <address>
        <city>Medan</city>
        <state>North Sumatera</state>
        <zip>20155</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <reference>
    <citation>Casado-Flores J, Blanco-Quirós A, Asensio J, Arranz E, Garrote JA, Nieto M. Serum procalcitonin in children with suspected sepsis: a comparison with C-reactive protein and neutrophil count. Pediatr Crit Care Med. 2003 Apr;4(2):190-5.</citation>
    <PMID>12749651</PMID>
  </reference>
  <results_reference>
    <citation>Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat Med. 2013 Nov;19(11):1423-37. doi: 10.1038/nm.3394. Review.</citation>
    <PMID>24202395</PMID>
  </results_reference>
  <results_reference>
    <citation>Engelhardt B, Vajkoczy P, Weller RO. The movers and shapers in immune privilege of the CNS. Nat Immunol. 2017 Feb;18(2):123-131. doi: 10.1038/ni.3666. Epub 2017 Jan 16. Review.</citation>
    <PMID>28092374</PMID>
  </results_reference>
  <results_reference>
    <citation>Deutschman CS. Acute-phase responses and SIRS/MODS: the good, the bad, and the nebulous. Crit Care Med. 1998 Oct;26(10):1630-1. Review.</citation>
    <PMID>9781714</PMID>
  </results_reference>
  <results_reference>
    <citation>Bambury RM, Teo MY, Power DG, Yusuf A, Murray S, Battley JE, Drake C, O'Dea P, Bermingham N, Keohane C, Grossman SA, Moylan EJ, O'Reilly S. The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme. J Neurooncol. 2013 Aug;114(1):149-54. doi: 10.1007/s11060-013-1164-9. Epub 2013 Jun 19.</citation>
    <PMID>23780645</PMID>
  </results_reference>
  <results_reference>
    <citation>Hatherill M, Tibby SM, Sykes K, Turner C, Murdoch IA. Diagnostic markers of infection: comparison of procalcitonin with C reactive protein and leucocyte count. Arch Dis Child. 1999 Nov;81(5):417-21.</citation>
    <PMID>10519716</PMID>
  </results_reference>
  <results_reference>
    <citation>Michelson N, Rincon-Torroella J, Quiñones-Hinojosa A, Greenfield JP. Exploring the role of inflammation in the malignant transformation of low-grade gliomas. J Neuroimmunol. 2016 Aug 15;297:132-40. doi: 10.1016/j.jneuroim.2016.05.019. Epub 2016 May 25. Review.</citation>
    <PMID>27397086</PMID>
  </results_reference>
  <results_reference>
    <citation>Sen E. Targeting inflammation-induced transcription factor activation: an open frontier for glioma therapy. Drug Discov Today. 2011 Dec;16(23-24):1044-51. doi: 10.1016/j.drudis.2011.09.003. Epub 2011 Sep 6. Review.</citation>
    <PMID>21920453</PMID>
  </results_reference>
  <results_reference>
    <citation>Tracey KJ, Cerami A. Tumor necrosis factor, other cytokines and disease. Annu Rev Cell Biol. 1993;9:317-43. Review.</citation>
    <PMID>8280464</PMID>
  </results_reference>
  <results_reference>
    <citation>D'Andrea A, Rengaraju M, Valiante NM, Chehimi J, Kubin M, Aste M, Chan SH, Kobayashi M, Young D, Nickbarg E, et al. Production of natural killer cell stimulatory factor (interleukin 12) by peripheral blood mononuclear cells. J Exp Med. 1992 Nov 1;176(5):1387-98.</citation>
    <PMID>1357073</PMID>
  </results_reference>
  <results_reference>
    <citation>Voll RE, Herrmann M, Roth EA, Stach C, Kalden JR, Girkontaite I. Immunosuppressive effects of apoptotic cells. Nature. 1997 Nov 27;390(6658):350-1.</citation>
    <PMID>9389474</PMID>
  </results_reference>
  <results_reference>
    <citation>Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001 Feb 17;357(9255):539-45. Review.</citation>
    <PMID>11229684</PMID>
  </results_reference>
  <results_reference>
    <citation>Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008 Jul 24;454(7203):436-44. doi: 10.1038/nature07205. Review.</citation>
    <PMID>18650914</PMID>
  </results_reference>
  <results_reference>
    <citation>Conti A, Gulì C, La Torre D, Tomasello C, Angileri FF, Aguennouz M. Role of inflammation and oxidative stress mediators in gliomas. Cancers (Basel). 2010 Apr 26;2(2):693-712. doi: 10.3390/cancers2020693.</citation>
    <PMID>24281089</PMID>
  </results_reference>
  <results_reference>
    <citation>Faria SS, Fernandes PC Jr, Silva MJ, Lima VC, Fontes W, Freitas-Junior R, Eterovic AK, Forget P. The neutrophil-to-lymphocyte ratio: a narrative review. Ecancermedicalscience. 2016 Dec 12;10:702. doi: 10.3332/ecancer.2016.702. eCollection 2016. Review.</citation>
    <PMID>28105073</PMID>
  </results_reference>
  <results_reference>
    <citation>Templeton AJ, Ace O, McNamara MG, Al-Mubarak M, Vera-Badillo FE, Hermanns T, Seruga B, Ocaña A, Tannock IF, Amir E. Prognostic role of platelet to lymphocyte ratio in solid tumors: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1204-12. doi: 10.1158/1055-9965.EPI-14-0146. Epub 2014 May 3. Review.</citation>
    <PMID>24793958</PMID>
  </results_reference>
  <results_reference>
    <citation>Zadora P, Dabrowski W, Czarko K, Smolen A, Kotlinska-Hasiec E, Wiorkowski K, Sikora A, Jarosz B, Kura K, Rola R, Trojanowski T. Preoperative neutrophil-lymphocyte count ratio helps predict the grade of glial tumor - a pilot study. Neurol Neurochir Pol. 2015;49(1):41-4. doi: 10.1016/j.pjnns.2014.12.006. Epub 2015 Jan 6.</citation>
    <PMID>25666772</PMID>
  </results_reference>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 11, 2020</study_first_submitted>
  <study_first_submitted_qc>November 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2020</study_first_posted>
  <last_update_submitted>November 11, 2020</last_update_submitted>
  <last_update_submitted_qc>November 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitas Sumatera Utara</investigator_affiliation>
    <investigator_full_name>Ridha Dharmajaya</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <keyword>Brain Tumor, Inflammation, Procalcitonin, CRP, NLR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

